Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer ...

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research ...

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for ...

Dianthus Therapeutics' DNTH103 is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing ...

Democratic Vice President Kamala Harris led Republican Donald Trump by a marginal three percentage points - 46% to 43% - as the two remain locked in a close race to win the Nov. 5 U.S ...

Poll Finds Harris Rising as She Challenges Trump on Change A national Times/Siena poll found Kamala Harris narrowly leading Donald Trump. Voters were more likely to see her, not Mr. Trump, as a ...